Premium
Long noncoding RNA PRKCQ‐AS1 promotes CRC cell proliferation and migration via modulating miR‐1287‐5p/YBX1 axis
Author(s) -
Cui Guoce,
Zhao HongLi,
Li Lina
Publication year - 2020
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.29712
Subject(s) - competing endogenous rna , gene knockdown , cancer research , gene silencing , long non coding rna , downregulation and upregulation , biology , cell growth , small hairpin rna , colorectal cancer , antisense rna , rna , microbiology and biotechnology , apoptosis , cancer , gene , genetics
Colorectal cancer (CRC) brings more than 600 000 deaths every year around the globe, making itself the third most frequently occurred carcinoma. The great progress human achieved in diagnosis and treatment of various cancers has failed to reverse this trend. Fortunately, growing evidence has implied the relationship between lncRNAs and cancer progression. Long noncoding RNA (lncRNA) PRKCQ‐AS1 was heightened in CRC cells and tissues and related with dismal prognosis of CRC patients. Knockdown of PRKCQ‐AS1 would induce a decrease in proliferative and migrating ability of CRC cells. Also, PRKCQ‐AS1 enriched in cytoplasm of CRC cells and negatively regulated miR‐1287‐5p level. More important, PRKCQ‐AS1 could bind to argonaute 2 and function in the RNA‐induced silencing complex with miR‐1287‐5p. Therefore, PRKCQ‐AS1 was a competing endogenous RNA for miR‐1287‐5p. Subsequently, it was validated that miR‐1287‐5p could suppress the proliferative and migratory functions in CRC. Furthermore, PRKCQ‐AS1 could upregulate the mRNA and protein level of YBX1 targeted by miR‐1287‐5p. And YBX1 expression was elevated in CRC cells and tissues. Rescue assays in vitro and in vivo showed that overexpression of YBX1 could partly offset the effect of CRC progression induced by knocking down PRKCQ‐AS1, demonstrating PRKCQ‐AS1 mediating CRC progression via miR‐1287‐5p/YBX1 pathway.